Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Medical Technologies Still Stumbling

publication date: Sep 1, 2009

After growing steadily for the past few years, China Medical (中国医疗技术公司) is facing a variety of problems: the company had to fight off charges of inaccurate financial reports; it had to lower prices for its ECLIA in vitro diagnostic tests, revenues are flattening for its FISH tests, and the buyer of its HIFU tumor therapy business wants a $15 million rebate (the SFDA has stopped sales of the device until the company completes an additional clinical trial). More details...

Stock Symbol: (NSDQ: CMED)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here